Methods The task force met to identify guideline sections and writing responsibilities, in
accordance with their clinical or laboratory knowledge, practice and expertise. Two task force …

This guideline update reflects substantial advances in the epidemiology, determinants,
pathophysiology, assessment, prevention and treatment of obesity, and shifts the focus of obesity …

The 2021 guidelines primary panel selected clinically relevant questions and produced
updated recommendations, on the basis of important new findings that have emerged since the …

Type 2 diabetes (T2D), obesity, and nonalcoholic fatty liver disease/nonalacoholic steatohepatitis
(NAFLD/NASH) share mutual causalities. Medications that may offer clinical benefits to …

Objective To systematically review evidence addressing the efficacy of testosterone replacement
therapy (TRT) and opioid tapering for opioid-induced hypogonadism among patients …

Background The 2021 Canadian Cardiovascular Society guidelines recommend proprotein
convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic …

Purpose Soluble fibre beneficially affects metabolism but whether it can augment the reductions
in glycemia induced through intensive weight management has not been extensively …

Background Walking and cardiovascular mortality are inversely associated in type 2
diabetes, but few studies have objectively measured associations of walking with individual …

Severe hypertriglyceridemia (HTG) is a relatively common form of dyslipidemia with a complex
pathophysiology and serious health complications. HTG can develop in the presence of …

Objective The anthropometric thresholds signaling type 2 diabetes risk have not been well
defined for Aboriginal communities. This study examined current thresholds in terms of ability …